Reading NVCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NVCT free→Reading NVCT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NVCT free→QuarterlyIQ Insights · NVCT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherw…
Results of Operations and Financial Condition. On February 11, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Results of Operations and Financial Condition. On November 4, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 22, 2025, the Board of Directors (the “Board”) of Nuvectis Pharma, Inc. (the “Company”) appointed Juan Sanchez, MD, to the Board. Dr. Sanchez will serve as a director until his term expires at the 2026 annual meeting of stockholders, at which time he will stand for election by the Company’s stockholders. Dr. Sanchez has (i) no arrangem…
Results of Operations and Financial Condition. On August 5, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or oth…
Other Events. Establishment of “At the Market” Offering Program On May 9, 2025, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”) as sales agent, pursuant to which the Company may offer and sell shares of its common stock, $0.00001 par value per share (the “Common Stock”), from time to time through Leerink Partners. The Company has filed a prospectus supplement (the “Prospectus S…
Results of Operations and Financial Condition. On May 6, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2025. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherw…
Results of Operations and Financial Condition. On February 25, 2025, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2024. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Entry into a Material Definitive Agreement. On February 5, 2025, Nuvectis Pharma, Inc. (“Nuvectis” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC (the “Underwriter”). Pursuant to the Underwriting Agreement, the Company agreed to sell to the Underwriter, in a firm commitment underwritten public offering (the “Offering”), 2,700,000 shares (the “Firm Shares”) of the Company’s common stock, $0.00001 par value per share (“Com…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.